Natural Product (NP) Details
| General Information of the NP (ID: NP9846) | |||||
|---|---|---|---|---|---|
| Name |
Phytosphingosine
|
||||
| Synonyms |
phytosphingosine; 554-62-1; (2S,3S,4R)-2-aminooctadecane-1,3,4-triol; 4-D-Hydroxysphinganine; D-Ribo-phytosphingosine; C18-Phytosphingosine; UNII-GIN46U9Q2Q; 4R-hydroxysphinganine; GIN46U9Q2Q; 1,3,4-Octadecanetriol, 2-amino-, (2S,3S,4R)-; (+)-D-ribo-Phytosphingosine; 4-R-hydroxyoctadecasphinganine; CHEBI:46961; 4-hydroxysphinganine; D-Ribo-1,3,4-trihydroxy-2-aminooctadecane; Phytosphingosin; C18H39NO3; DS-phytosphingosine; phytosphingosine group; 4D-Hydroxysphinganine; 4-D-hydroxy-Sphinganine; EC 439-210-6; SCHEMBL20110; C18-PHS; CHEMBL236036; DTXSID80203951; ZINC8437018; 5544AE; ANW-32318; LMSP01030001; MFCD02259274; AKOS015949172; AKOS016015084; CCG-208251; CS-W012019; DB14119; FS-5977; HY-W011303; D-ribo-2-amino-1,3,4-Octadecanetriol; SMP2_000142; NCGC00163609-01; P1765; (2S,3S,4R)-2-Amino-1,3,4-octadecanetriol; C12144; SR-05000002328; J-501034; Q3746193; SR-05000002328-2; (2S,3S,4R)-2-Amino-1,3,4-octadecanetriol, AldrichCPR; [2S-(2R*,3R*,4S*)]-2-amino-1,3,4-Octadecanetriol; 1,3,4-Octadecanetriol, 2-amino-, (2S-(2R*,3R*,4S*))-; D-ribo-Phytosphingosine, 4-hydroxysphinganine (Saccharomyces Cerevisiae), powder
Click to Show/Hide
|
||||
| Species Origin | Patiria pectinifera ... | Click to Show/Hide | |||
| Patiria pectinifera | |||||
| Disease | Skin inflammation [ICD-11: ME66] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C18H39NO3
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CCCCCCCCCCCCCCC(C(C(CO)N)O)O
|
||||
| InChI |
1S/C18H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17(21)18(22)16(19)15-20/h16-18,20-22H,2-15,19H2,1H3/t16-,17+,18-/m0/s1
|
||||
| InChIKey |
AERBNCYCJBRYDG-KSZLIROESA-N
|
||||
| CAS Number |
CAS 554-62-1
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Gamma-ray irradiation | Brain metastases | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Induction | AIF nuclear translocation | ||||
| Induction | Bax mitochondrial relocalization | |||||
| Induction | ROS accumulation | |||||
| In-vitro Model | Jurkat | CVCL_0065 | T acute lymphoblastic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Enhancement of cell death of radiation-resistant cancer cells by phytosphingosine treatment in combination with gamma-radiation is mediated by nuclear translocation of AIF, which is in turn mediated both by ROS-dependent Bax relocalization and ROS-independent PARP-1 activation. | |||||
| TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TRAIL-R1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Jurkat | CVCL_0065 | T acute lymphoblastic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Phytosphingosine sensitizes cancer cells to TRAIL through the synergistic up-regulation of DR4 and DR5 in an NF-kappaB-dependent fashion resulting in caspase-8 activation and subsequent mitochondrial dysfunction. | |||||
